LevitasBio Launches LeviSelect Suite of Cell Depletion & Enrichment Kits
7.2.2023 15:53:00 EET | Business Wire | Press release
LevitasBio, Inc. (www.levitasbio.com), a premier end-to-end sample processing and cellular analysis provider to the life sciences market, unveils a suite of LeviSelect™ cell depletion and enrichment kits for immunology research.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005645/en/
Five new LeviSelect Immune Cell Kits enable targeted enrichment of CD3 T Cells, CD4 T Cells, CD8 T Cells and Pan B Cells. Additional kits are also available under early access. (Graphic: Business Wire)
LeviSelect Kits are a targeted expansion of the revolutionary LeviCell™ Advanced Workflow fully integrated protocol that delivers an important new approach to cellular isolation and analysis, offering:
- Cells of interest are entirely label-free, unmodified or unperturbed with no gene expression or activation changes
- Live-cell enrichment, debris removal, and targeted selection all occur in a single simple step with no additional purifications, filtrations or consumables required
- Multiple LeviSelect kits can be multiplexed for a powerful and extremely targeted approach
For oncology or immuno-oncology research, LeviSelect CD45 Depletion Kits provide a highly effective method for the enrichment of pure tumor cells enabling characterization for drug discovery and biomarker identification.
LeviSelect Immune Kits support target selection of the immune subpopulations required for downstream cell analysis or further subsetting. Researchers can enrich hematopoietic populations quickly without lengthy workflows or potential cell activation.
- CD3 Enrichment
- CD4 Enrichment
- CD8 Enrichment
- Pan B Enrichment
- Pan Monocyte Enrichment
- NK Cell Enrichment
- Neutrophil Enrichment
Now T Cells, B Cells, NK Cell and Monocytes can be enriched simultaneously with viable cell enrichment in an untouched and unbiased manner. Future LeviSelect kits will include subtypes from these major populations.
“With the immediate launch of seven LeviSelect Kits—and six more available via our Early Access program—LevitasBio is enabling the streamline enrichment of these cells for downstream cell-based assays or immune profiling studies,” stated Martin Pieprzyk, CEO of LevitasBio. “This is highly impactful to catalyze novel discoveries in both academic and biopharma discovery research.”
Researchers, scientists, and labs who would like exclusive, priority access to future LeviSelect Kits can join the LevitasBio Early Access Program at https://levitasbio.com/early-access-program.
LevitasBio —True Biology Begins Here
Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005645/en/
Contact information
Steven Collier
Communication Liaison
steve@levitasbio.com
650-229-8596
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 23:08:00 EEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 22:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, security, and performance required for enterprise environments. These capabilities enable organizations to move from pilot to production with confiden
BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 20:27:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513542161/en/ BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. Michael Wang, M.D., Global Principal Investigator
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this vision is colliding with skyrocketing cloud costs and trapped data. For many, layering agents onto a fragmented landscape only magnifies govern
Boomi and Couchbase Partner to Power Enterprise AI Agents with Trusted Recollection, Connectivity, and Governance13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, and Couchbase, Inc., the operational data platform for AI, today announced a partnership through which the two companies are collaborating closely to accelerate AI pilots to production. The companies will co-engineer solutions that give customers a production-ready foundation for agentic AI, combining Boomi's connectivity, runtime, and governance for AI agents with Couchbase's scalable recollection and vector capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513350337/en/ Enterprises deploying AI agents today face a common challenge: while agents perform well in pilots, they struggle to scale due to inconsistent access to trusted context, recollection, and real-time business data. Lack of governance, auditability, and operational control drives up compute costs while diminishing productivity and revenue. “2026 is the year organizations move from AI experimentation to a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom